Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple MyelomaBlood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseActive, not recruitingPhase 22026-03-17NCT06353022

2 results · Page 1 of 1

Swipe the table sideways for more columns.

19 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
APHP Hôpital La Pitié SalpétrièreParisFrance1
APHP Hôpital Saint-AntoineParisFrance1
CH de la Côte BasqueBayonneFrance4
CH Lyon sudLyonFrance3
CHD VendeeLa Roche-sur-YonFrance9
CHRU DIjonDijonFrance1
CHRU LILLE - Hôpital Claude HuriezLilleFrance2
CHRU Nancy - Hôpitaux de BraboisVandœuvre-lès-NancyFrance2
CHRU Rennes - Hôpital de PontchaillouRennesFrance1
CHU BORDEAUX - Hôpital du Haut LévêquePessacFrance1
CHU caenCaenFrance18
Chu de NantesNantesFrance72
CHU de Strasbourg (HUS)StrasbourgFrance1
CHU LimogesLimogesFrance14
CHU MontpellierMontpellierFrance23
CHU PoitiersPoitiersFrance32
CHU ToulouseToulouseFrance19
CHU Tours Hôpital BretonneauToursFrance1
IPC Marseille Institut Paoli CalmettesMarseilleFrance1